Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Tolerability of Laquinimod

- Relapsing Multiple Sclerosis
- Withdrawn

Study Title: A Multinational, Randomized, Double-blind, ParFemale, Maleel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Teva Identifier: LAQ-MS-201

ClinicalTrials.gov Identifier: NCT01404117

Study Status: Withdrawn

Trial Condition(s): Relapsing Multiple Sclerosis

Interventions: Drug: Laquinimod 0.6 | Drug: Laquinimod 1.2 | Other: Glatiramer Acetate or interferon-beta+ Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: 03/01/2012 - 01/01/2014

Phase: Phase 2

Study Type

Interventional